Pain Intensity, Illness Duration, and Protein Catabolism in Temporomandibular Disorder Patients with Chronic Muscle Pain

Aims: To investigate whether the duration of chronic pain in tem-poromandibular disorder (TMD) patients is associated with a net depletion of amino acids, and a distinct process from pain inten-sity. Methods: Twenty-nine patients defined by the research diag-nostic criteria/TMD as having Type 1a muscle pain (TMD1A group), and 34 age- and sex-matched control subjects, were assessed for variation in urinary organic and amino acid excretion by gas chromatograph-mass spectrometry. Results: The TMD1A patients’ mean pain intensity, assessed on a visual analog scale (VAS), was 5.4 (95% confidence limits: 4.5 to 6.3), TMD1A ill-ness duration was 5.0 ± 1.2 (SD) years, number of body areas with pain/subject was 6.3 ± 2.4 (range 0 to 10), and symptom prevalence from the Symptom Check List-90-Revised (SCL-90-R) was 25.5 ± 11.3 symptoms/subject, which was higher than the controls (5.2 ± 5.0 symptoms/subject, P ＜ .001). TMD1A patient illness duration was positively correlated with symptom preva-lence and body pain distribution, and all were independent of pain intensity. The TMD1A patients had: (1) an increased tyrosine:leucine ratio; and (2) reduced leucine concentrations (both P ＜ .001), which suggests deregulated catabolism. Pain intensity was associated with: (1) changes in the multivariate uri-nary metabolite excretion patterns (P ＜ .001); (2) reduced leucine concentrations (P ＜ .001); and (3) increases in total urinary metabolites (P ＜ .04), and in 2 unidentified molecules, UM28 (P ＜ .001) and CFSUM1 (P ＜ .002). TMD1A illness duration was associated with lower (1) urinary metabolite concentrations and (2) succinic acid and combined glutamine + glutamic acid levels, suggesting a progressive depletion of metabolite reserves. Conclusion: In TMD1A patients, total amino acid excretion was positively correlated with pain intensity and negatively correlated with illness duration, which indicated that illness duration was associated with a different set of metabolic anomalies compared with those identified for pain intensity.

pain; facial pain; fibromyalgia syndrome; temporomandibular joint dysfunction

1. LeResche L, Fricton J, Mohl N, et al. Research diagnostic criteria. Part II. J Craniomandib Disord 1992;6:327–334.

2. McGregor NR, Butt HL, Zerbes M, Dunstan RH, Roberts TK, Klineberg IJ. Assessment of pain (distribution & onset), symptoms, SCL-90-R inventory responses and the association with infectious events in patients with chronic orofacial pain. J Orofac Pain 1996;10:339–350.

3. Pullinger AG, Seligman DA, Solberg WK. Temporo-mandibular disorders. Part I: Functional status, dentomor-phological features, and sex differences in a non-patient population. J Prosthet Dent 1988;59:228–235.

4. Pedersen A, Hansen HJ. Long-term evaluation of 211 patients with internal derangement of the temporo-mandibular joint. Comm Dent Oral Epidemiol 1987; 15:344–347.

5. Russell IJ, Michalek JE, Vipraio GA, Fletcher EM, Wall K. Serum amino acids in fibrositis/fibromyalgia syndrome. J Rheumatol 1989;16:158–163.

6. Yunus MB, Dailey JW, Aldag JC, Masi AT, Jobe PC. Plasma tryptophan and other amino acids in primary fibromyalgia: A controlled study. J Rheumatol 1992;19: 90–94.

7. McGregor NR, Dunstan RH, Zerbes M, Butt HL, Roberts TK, Klineberg IJ. Chronic fatigue syndrome: I. Preliminary determination of a molecular basis to chronic fatigue syndrome. Biochem Mol Med 1996;57:73–80.

8. McGregor NR, Dunstan RH, Zerbes M, Butt HL, Roberts TK, Klineberg IJ. Preliminary determination of the association between symptom expression and urinary metabolites in subjects with chronic fatigue syndrome. Biochem Mol Med 1996;58:85–92.

9. McGregor NR, Dunstan RH, Zerbes M, Butt HL, Roberts TK, Klineberg IJ. A preliminary assessment of the association of SCL-90-R psychological inventory responses with changes in urinary metabolites in patients with chronic fatigue syndrome. J Chronic Fatigue Synd 1996;3:17–36.

10. Coderre TJ. The role of excitatory amino acid receptors and intracellular messengers in persistent nociception after tissue injury in rats. Mol Neurobiol 1993;7:229–246.

11. Cleare AJ, Bearn J, Allain T, et al. Contrasting neuroen-docrine responses in depression and chronic fatigue syndrome. J Affect Dis 1995;35:283–289.

12. Moeller FG, Steinberg JL, Fulton M, Kramer G, Petty F. A preliminary neuroendocrine study with buspirone in major depression. Neuropsychopharmacology 1994;10:75–83.

13. Mortimore GE, Poso AR. Intracellular protein catabolism and its control during nutrient deprivation and supply. Annu Rev Nutr 1987;7:539–564.

14. Goodman MN. Interleukin-6 induces skeletal muscle protein breakdown in rats. Proc Soc Exp Biol Med 1994;205: 182–185.

15. Haussinger D, Hallbrucker C, vom Dahl S, et al. Cell volume is a major determinant of proteolysis control in liver. FEBS Lett1991;283:70–72.

16. Balavoine S, Feldmann G, Lardeux B. Regulation of RNA degradation in cultured rat hepatocytes: Effects of specific amino acids and insulin. J Cell Physiol 1993;156:56–62.

17. Simmons PS, Miles JM, Gerich JE, Haymond MW. Increased proteolysis. An effect of increases in plasma cortisol within thephysiologic range. J Clin Invest 1994;73:412–420.

18. Fryburg DA, Barrett EJ. Growth hormone acutely stimulates skeletal muscle but not whole-body protein synthesis in humans. Metabolism 1993;42:1223–1227.

19. Jimenez Jimenez FJ, Ortiz Leyba C, Morales Menedez S, Barros Perez M, Munoz Garcia J. Prospective study on the efficacy of branched-chain amino acids in septic patients. J Parenter Enteral Nutr 1991;15:252–261.

20. Hama AT, Sagen J. Induction of spinal NADPH-diaphorase by nerve injury is attenuated by adrenal medullary transplants. Brain Res 1994;640:345–351.

21. Jeevanandam M. Trauma and sepsis. In: Cynober LA (ed). Amino Acid Metabolism and Therapy in Health and Nutritional Disease. New York: CRC Press, 1995:245–255.

22. Greiwe JS, Kwon G, McDaniel ML, Semenkovich CF. Leucine and insulin activate p70 S6 kinase through different pathways in human skeletal muscle. Am J Physiol Endocrinol Metab 2001;281:E466–E471.

23. Vary TC, Jefferson LS, Kimball SR. Amino acid-induced stimulation of translation initiation in rat skeletal muscle. Am J Physiol 1999;277:E1077–E1086.

24. Suhadolnik RJ, Reichenbach NL, Hitzges P, et al. Up regula-tion of the 2-5A Synthase/RNase L pathway associated with chronic fatigue syndrome. Clin Infect Dis 1994;18:S96–S104.

25. Young VR. The role of skeletal and cardiac muscle in the regulation of protein metabolism. In: Munro HM (ed). Vol 4: Mammalian Protein Metabolism. New York: Academic Press, 1970:586–674.

26. Pacy PJ, Read M, Peters TJ, Halliday D. Post-absorptive whole body leucine kinetics and quadriceps muscle protein synthetic rate (MPSR) in the post-viral syndrome. Clin Sci 1988;75:36–37.

27. Coderre TJ, Yashpal K. Intracellular messengers con-tributing to persistent nociception and hyperalgesia induced by L-glutamate and substance P in the rat forma-lin pain model. Eur J Neurosci 1994;6:1328–1334.

28. Tavalin SJ, Ellis EF, Satin LS. Inhibition of the electrogenic Na pump underlies delayed depolarization of cortical neurons after mechanical injury or glutamate. J Neurophysiol 1997;77:632–638.

29. Seligman DA, Pullinger AG, Solberg WK. Temporo-mandibular disorders. Part III: Occlusal and articular factors associated with muscle tenderness. J Prosthet Dent 1988;59:483–489.

30. Weinberg LA, Lager LA. Clinical report on the etiology and diagnosis of TMJ dysfunction-pain syndrome. J Prosthet Dent 1980;44:642–653.

31. Fricton JR, Kroening R, Haley D, Siegert R. Myofascial pain syndrome of the head and neck: A review of the clinical characteristics of 164 patients. Oral Surg Oral Med Oral Pathol 1985;60:615–619.

32. Carraro JJ, Quirch JS, Albano E. Analysis of patients with temporomandibular joint pain. J Prosthet Dent 1969; 21:639–644.

33. Turp JC, Kowalski CJ, O’Leary N, Stohler CS. Pain maps from facial pain patients indicate a broad pain geography. J Dent Res 1998;77:1465–1472.

34. Giesecke K, Magnusson I, Ahlberg M, Hagenfeldt L, Wahren J. Protein and amino acid metabolism during early starvation as reflected by excretion of urea and methylhistidines. Metabolism 1989;38:1196–1200.

35. Sjolin J, Stjernstrom H, Henneberg S, et al. Splanchnic and peripheral release of 3-methylhistidine in relation to its urinary excretion in human infection. Metabolism 1989; 38:23–29.

36. Dusheiko G. Side effects of alpha interferon in chronic hepatitis C. Hepatol 1997;26:112S–121S.

37. Valentine AD, Meyers CA, Kling MA, Richelson E, Hauser P. Mood and cognitive side effects of interferon-alpha therapy. Semin Oncol 1998;25:39–47.

38. Bowles NE, Bayston TA, Zhang HY, et al. Persistence of enterovirus RNA in muscle biopsy samples suggests that some cases of chronic fatigue syndrome result from a previous, inflammatory viral myopathy. J Med 1993;24:145–160.

39. Gow JW, Behan WM, Simpson K, McGarry F, Keir S, Behan PO. Studies on enterovirus in patients with chronic fatigue syndrome. Clin Infect Dis 1994;18:S126–S129.

40. Butt HL, Dunstan RH, McGregor NR, Roberts TK, Zerbes M, Klineberg IJ. An association of membrane damaging toxins from coagulase negative staphylococcus and chronic orofacial muscle pain. J Med Microbiol 1998;47:577–584.

41. Mehlin C, Headley CM, Klebanoff SJ. An inflammatory polypeptide complex from Staphylococcus epidermidis: Isolation and characterization. J Exp Med 1999;189: 907–918.

42. Hasselgren PO. Counter-regulatory hormones and the role of cytokines in the control of amino acid metabolism. In: Cynober LA (ed). Amino Acid Metabolism and Therapy in Health and Nutritional Disease. New York: CRC Press, 1995:139–156.

43. Lacey JM, Wilmore DW. Is glutamine a conditionally essential amino acid? Nutr Rev 1990;48:297–302.

44. Souba WW. Glutamine: A key substrate for the splanchnic bed. Annu Rev Nutr 1991;11:285–308.

45. Oles RD. Glucose intolerance associated with temporo-mandibular joint pain-dysfunction syndrome. Oral Surg Oral Med Oral Pathol 1978;43:546–553.

46. Bralley JA, Lord RS. Treatment of chronic fatigue syndrome with specific amino acid supplementation. J Applied Nutr 1994;46:74–78.

47. Hattori Y, Campbell EB, Gross SS. Argininosuccinate synthetase mRNA and activity are induced by immunostimulants in vascular smooth muscle. Role in the regeneration or arginine for nitric oxide synthesis. J Biol Chem 1994; 269:9405–9408.

48. Geng Y, Hansson GK, Holme E. Interferon-gamma and tumor necrosis factor synergize to induce nitric oxide production and inhibit mitochondrial respiration in vascular smooth muscle cells. Circ Res 1992;71:1268–1276.

49. Bolanos JP, Peuchen S, Heales SJ, Land JM, Clark JB. Nitric oxidemediated inhibition of the mitochondrial respiratory chain in cultured astrocytes. J Neurochem 1994;63:910–916.

50. Dijkmans R, Billiau A. Interferon-gamma/lipopolysaccharide-treated mouse embryonic fibroblasts are killed by a glycolysis/L-arginine-dependent process accompanied by depression of mitochondrial respiration. Eur J Biochem 1991;202:151–159.

51. McGregor NR, Zerbes M, Niblett SH, et al. Coagulase-negative staphylococcal membrane-damaging toxins, pain intensity, and metabolic changes in temporomandibular disorder patients with chronic muscle pain. J Orofac Pain 2003;17:125–132.